Pyruvic acid
|
Basic information |
| Metabolite name | Pyruvic acid |
 | HMDB0000243 |
 |
C00022 |
 |
1060 |
| Synonyms | pyruvate |
| No. of studies | 44 |
|
Basic information |
| Metabolite name | Pyruvic acid |
| HMDB0000243 |
|
C00022 |
|
1060 |
| Synonyms | pyruvate |
| No. of studies | 44 |
|
Relationship between Pyruvic acid and depression (count: 44) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M014 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M014 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M014 | Type2 | CUMS + XY-A group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M016 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M021 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M027 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M027 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Up |
| Study M035 | Type1 | depressed suicide attempters group vs. control group | Plasma | Human | Down |
| Study M038 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M038 | Type2 | CUMS + high dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M038 | Type2 | CUMS + middle dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M038 | Type2 | CUMS + low dose of FFCGF group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M038 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M038 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M058 | Type1 | depressed HBV-infected patients group vs. control group and non-depressed HBV-infected group | Urine | Human | Up |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + high dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + middle dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + low dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M078 | Type1 | CORT model group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M078 | Type2 | CORT model + icariin group vs. CORT model group | Serum | Sprague-Dawley rat | Up |
| Study M085 | Type3 | ketamine group vs. control group at 24 h after treatment | Urine | Cynomolgus monkey | Down |
| Study M097 | Type1 | depressed men group vs. control men group | Urine | Human | Down |
| Study M1057 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Up |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Down |
| Study M116 | Type3 | LY group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M116 | Type3 | ketamine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M118 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M133 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M133 | Type2 | CUMS + XY-A group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M207 | Type1 | depressed group vs. control group | Faece | Kunming mouse | Down |
| Study M475 | Type1 | dHB group vs. HB group | Urine | Human | Up |
| Study M486 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Down |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M543 | Type1 | summer depression group vs. summer control group | Plasma | Human | Up |
| Study M564 | Type1 | ACTH group vs. control group | Urine | Wistar rat | Down |
| Study M577 | Type1 | male depression group vs. male control group, aged 20-29 | Plasma | Human | Unknown |
| Study M584 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + high dose of negative control treatment group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + low dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + high dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + low dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M602 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Ventral hippocampus | C57BL/6 J mouse | Down |
| Study M614 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M614 | Type2 | CUMS + aerobic training group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M685 | Type1 | SDS group vs. control group | Nucleus accumbens | C57BL/6J mouse | Up |
| Study M762 | Type1 | corticosterone group vs. control group | Liver | Wistar rat | Up |
| Study M762 | Type2 | corticosterone + metformin group vs. corticosterone group | Liver | Wistar rat | Down |
| Study M788 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M815 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M815 | Type2 | CUMS + low dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + high dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M844 | Type1 | CORT group vs. control group | PC12 cell | Rat | Down |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Down |
| Study M921 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M924 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M924 | Type2 | CUMS + aerobic exercise group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M953 | Type1 | CRS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M966 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M966 | Type2 | CUMS + Xiaoyao San group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M966 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |